Bioavailability of berberine: challenges and solutions

Yıl 2021, Cilt: 51 Sayı: 1, 141 - 153, 30.04.2021

Asha Thomas Seema Kamble Sanjeevani Deshkar Lata Kothapalli Sohan Chitlange

Öz

Berberine is a quaternary benzylisoquinoline alkaloid with multiple pharmacological effects used for the treatment of hypertension, tumors, bacterial infections, inflammation, HIV, and cardiac diseases. In phase I clinical trials, berberine is safe at excessive doses but manifests poor bioavailability. Major challenges like poor absorption, rapid metabolism, and rapid systemic elimination are responsible for low plasma and tissue levels of berberine. Various strategies have been undertaken by several researchers to overcome this issue and enhance the bioavailability of berberine. This includes the design of new formulation strategies; novel drug delivery systems (NDDS) like liposomes, nanosized dosage forms, phospholipid complexes, mucoadhesive microparticles, and micoemulsions; the use of adjuvants; and the design of structural analogous of berberine. This review focuses on the occurrence of berberine in numerous plants and its pharmacological activities as evidenced through numerous preclinical and clinical studies. The later part of this review highlights the bioavailability issue of berberine which arises due to its poor absorption, elevated rate and extent of metabolism, and quick elimination and clearance from the body. A systematic effort has beenmade to analyze the various formulation strategies, including the design of newer berberine analogues and derivatives. These strategies can be further explored to increase the bioavailability, medicinal value, and application of this promising molecule.

Anahtar Kelimeler

Berberine, bioavailability improvement, metabolism, pharmacokinetics

Kaynakça

• • Affuso, F., Ruvolo, A., Micillo, F., Saccà, L., & Fazio, S. (2010). Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study. Nutrition, Metabolism and Cardiovascular Diseases, 20(9), 656-661.
• • Affuso, F., Mercurio, V., Ruvolo, A., Pirozzi, C., Micillo, F., Carlomagno, G., ... & Fazio, S. (2012). A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome. World journal of cardiology, 4(3), 77.
• • Agarwal, M., Srivastava, V. K., Saxena, K. K., & Kumar, A. (2006). Hepatoprotective activity of Beta vulgaris against CCl4-induced hepatic injury in rats. Fitoterapia, 77(2), 91-93.
• • Ali, H., Uddin, S., & Jalal, S. (2015). Chemistry and biological activities of Berberis lyciumRoyle. Journal of Biologically Active Products from Nature, 5(5), 295-312.
• • Andreicuţ, A. D., Parvu, A. E., Moț, A. C., Parvu, M., Fischer-Fodor, E. V. A., Feldrihan, V., ... & Irimie, A. (2018). Anti-inflammatory and antioxidant effects of Mahonia aquifolium leaves and bark extracts. Farmacia, 66(1).
• • Bajpai, D., & Vankar, P. S. (2007). Antifungal textile dyeing withmahonianapaulensis dc leaves extract based on its antifungal activity. Fibers and Polymers, 8(5), 487.
• • Battu, S. K., Repka, M. A., Maddineni, S., Chittiboyina, A. G., Avery, M. A., & Majumdar, S. (2010). Physicochemical characterization of berberine chloride: a perspective in the development of a solution dosage form for oral delivery. Aaps Pharmscitech, 11(3), 1466-1475.
• • Bhandari, D. K., Nath, G., Ray, A. B., & Tewari, P. V. (2000). Antimicrobial activity of crude extracts from Berberis asiatica stem bark. Pharmaceutical Biology, 38(4), 254-257.
• • Biswas, T. K., & Mukherjee, B. (2003). Plant medicines of Indian origin for wound healing activity: a review. The International Journal of Lower Extremity Wounds, 2(1), 25-39.
• • Čerňáková, M., & Košťálová, D. (2002). Antimicrobial activity of berberine—A constituent of Mahonia aquifolium. Folia Microbiologica, 47(4), 375-378.
• • Chang, C. H., Huang, W. Y., Lai, C. H., Hsu, Y. M., Yao, Y. H., Chen, T. Y., ... & Lin, Y. H. (2011). Development of novel nanoparticles shelled with heparin for berberine delivery to treat Helicobacter pylori. Acta Biomaterialia, 7(2), 593-603.
• • Chatterjee, P., & Franklin, M. R. (2003). Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metabolism and Disposition, 31(11), 1391-1397.
• Chen, F., Zhang, Y., Liu, Q., Pang, M. Z., Yang, X. G., & Pan, W. S. (2008). Optimization of a novel mucoadhesive drug deliver system with ion-exchange resin core loaded with berberine hydrochloride using central composite design methodology. Yao xuexue bao= Acta Pharmaceutica Sinica, 43(9), 963-968.
• • Chen, W., Miao, Y. Q., Fan, D. J., Yang, S. S., Lin, X., Meng, L. K., & Tang, X. (2011). Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats. Aaps Pharmscitech, 12(2), 705-711.
• • Cicero, A. F., Rovati, L. C., & Setnikar, I. (2007). Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents. Arzneimittelforschung, 57(01), 26- 30.
• • Das, N. G., Rabha, B., Talukdar, P. K., Goswami, D., & Dhiman, S. (2016). Preliminary in vitro antiplasmodial activity of Aristolochiagriffithii and Thalictrum foliolosum DC extracts against malaria parasite Plasmodium falciparum. BMC Research Notes, 9(1), 51.
• • Das, S., Das, M. K., Mazumder, P. M., Das, S., & Basu, S. P. (2009). Cytotoxic activity of methanolic extract of Berberis aristata DC on colon cancer. Global Journal of Pharmacology, 3(3), 137-140.
• • Deng, Y., Liao, Q., Li, S., Bi, K., Pan, B., & Xie, Z. (2008). Simultaneous determination of berberine, palmatine and jatrorrhizine by liquid chromatography–tandem mass spectrometry in rat plasma and its application in a pharmacokinetic study after oral administration of coptis–evodia herb couple. Journal of Chromatography B, 863(2), 195-205.
• • Elsheikh, M. A., Elnaggar, Y. S., Hamdy, D. A., & Abdallah, O. Y. (2018). Novel cremochylomicrons for improved oral bioavailability of the antineoplastic phytomedicine berberine chloride: Optimization and pharmacokinetics. International Journal of Pharmaceutics, 535(1-2), 316-324.
• • Eto, T., Inoue, S., & Kadowaki, T. (2012). Effects of once‐daily teneligliptin on 24‐h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4‐week, randomized, double‐blind, placebo‐controlled trial. Diabetes, Obesity and Metabolism, 14(11), 1040-1046.
• • Ettefagh, K. A., Burns, J. T., Junio, H. A., Kaatz, G. W., & Cech, N. B. (2011). Goldenseal (Hydrastis canadensis L.) extracts synergistically enhance the antibacterial activity of berberine via efflux pump inhibition. Planta Medica, 77(08), 835-840.
• • Godugu, C., Patel, A. R., Doddapaneni, R., Somagoni, J., & Singh, M. (2014). Approaches to improve the oral bioavailability and effects of novel anticancer drugs berberine and betulinic acid. PloS one, 9(3), e89919.
• • Gong, Z., Chen, Y., Zhang, R., Wang, Y., Guo, Y., Yang, Q., ... & Zhu, X. (2014a). Pharmacokinetic comparison of berberine in rat plasma after oral administration of berberine hydrochloride in normal and post inflammation irritable bowel syndrome rats. International journal of molecular sciences, 15(1), 456-467.
• • Gong, Z., Chen, Y., Zhang, R., Wang, Y., Yang, Q., Guo, Y., ... & Wang, Y. (2014). Pharmacokinetics of two alkaloids after oral administration of Rhizoma Coptidis extract in normal rats and irritable bowel syndrome rats. Evidence-Based Complementary and Alternative Medicine, 2014.
• • Gulfraz, M., Mehmood, S., Ahmad, A., Fatima, N., Praveen, Z., & Williamson, E. M. (2008). Comparison of the antidiabetic activity of Berberis lyceum root extract and berberine in alloxan‐induced diabetic rats. Phytotherapy Research, 22(9), 1208-1212.
• • Gui, S. Y., Wu, L., Peng, D. Y., Liu, Q. Y., Yin, B. P., & Shen, J. Z. (2008). Preparation and evaluation of a microemulsion for oral delivery of berberine. Die Pharmazie-An International Journal of Pharmaceutical Sciences, 63(7), 516-519.
• • Gurley, B. J., Swain, A., Hubbard, M. A., Hartsfield, F., Thaden, J., Williams, D. K., ... & Tong, Y. (2008). Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. Clinical Pharmacology & Therapeutics, 83(1), 61-69.
• • Hu, Y. L., Chen, C., Zou, Z. Y., Li, X. G., & Ye, X. L. (2014). Comparative study of pharmacokinetics and tissue distribution of 8-cetylberberine and berberine in rats. Acta Pharmaceutica Sinica, 49(11), 1582.
• • Hussain, M. A., Khan, M. Q., Habib, T., & Hussain, N. (2011). Antimicronbial activity of the crude root extract of Berberis lycium Royle. Advances in Environmental Biology, 5(4), 585-588.
• • Iizuka, N., Miyamoto, K., Okita, K., Tangoku, A., Hayashi, H., Yosino, S., ... & Oka, M. (2000). Inhibitory effect of Coptidis Rhizoma and berberine on the proliferation of human esophageal cancer cell lines. Cancer Letters, 148(1), 19-25.
• • Inbaraj, J. J., Kukielczak, B. M., Bilski, P., Sandvik, S. L., & Chignell, C. F. (2001). Photochemistry and photocytotoxicity of alkaloids from Goldenseal (Hydrastis canadensis L.) 1. Berberine. Chemical Research in Toxicology, 14(11), 1529-1534.
• • Jia, J., Zhang, K., Zhou, X., Ma, J., Liu, X., Xiang, A., & Ge, F. (2019). Berberine-loaded solid proliposomes prepared using solution enhanced dispersion by supercritical CO2: Sustained release and bioavailability enhancement. Journal of Drug Delivery Science and Technology, 51, 356-363.
• • Jia, Y., Xu, B., & Xu, J. (2017). Effects of type 2 diabetes mellitus on the pharmacokinetics of berberine in rats. Pharmaceutical Biology, 55(1), 510-515.
• • Jigneshkumar, P. R. (2011). Evaluation of the Antihyperglycemic, Cardio protective and Antihyperlipidemic activity of flowers of Sesbania grandiflora (Linn) (Doctoral dissertation, RGUHS).
• • Joshi, P. V., Shirkhedkar, A. A., Prakash, K., & Maheshwari, V. L. (2011). Antidiarrheal activity, chemical and toxicity profile of Berberis aristata. Pharmaceutical Biology, 49(1), 94-100.
• • Kawanishi, N., Sugimoto, T., Shibata, J., Nakamura, K., Masutani, K., Ikuta, M., & Hirai, H. (2006). Structure-based drug design of a highly potent CDK1, 2, 4, 6 inhibitor with novel macrocyclic quinoxalin-2-one structure. Bioorganic & Medicinal Chemistry Letters, 16(19), 5122-5126.
• • Kobayashi, Y., Yamashita, Y., Fujii, N., Takaboshi, K., Kawakami, T., Kawamura, M., ... & Nakano, H. (1995). Inhibitors of DNA topoisomerase I and II isolated from the Coptis rhizomes. Planta Medica, 61(05), 414-418.
• • Kong, W. J., Wei, J., Zuo, Z. Y., Wang, Y. M., Song, D. Q., You, X. F., ... & Jiang, J. D. (2008). Combination of simvastatin with berberine improves the lipid-lowering efficacy. Metabolism, 57(8), 1029-1037.
• • Kong, W. J., Wei, J., Zuo, Z. Y., Wang, Y. M., Song, D. Q., You, X. F., ... & Jiang, J. D. (2008). Combination of simvastatin with berberine improves the lipid-lowering efficacy. Metabolism, 57(8), 1029-1037.
• • Kong, W. J., Zhao, Y. L., Xiao, X. H., Wang, J. B., Li, H. B., Li, Z. L., ... & Liu, Y. (2009). Spectrum–effect relationships between ultra performance liquid chromatography fingerprints and anti-bacterial activities of Rhizoma coptidis. Analytica Chimica Acta, 634(2), 279- 285.
• • Lee, H. W., Suh, J. H., Kim, H. N., Kim, A. Y., Park, S. Y., Shin, C. S., ... & Kim, J. B. (2008). Berberine promotes osteoblast differentiation by Runx2 activation with p38 MAPK. Journal of Bone and Mineral Research, 23(8), 1227-1237.
• • Lee, M. K., Zhang, Y. H., & Kim, H. S. (1996). Inhibition of tyrosine hydroxylase by palmatine. Archives of Pharmacal Research, 19(4), 258.
• • Li, Y. H., Yang, P., Kong, W. J., Wang, Y. X., Hu, C. Q., Zuo, Z. Y., ... & Du, N. N. (2009). Berberine Analogues as a novel class of the lowdensity- lipoprotein receptor up-regulators: synthesis, structure− activity relationships, and cholesterol-lowering efficacy. Journal of Medicinal Chemistry, 52(2), 492-501.